Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Saphnelo® (anifrolumab-fnia) – New drug approval
August 2, 2021 - AstraZeneca announced the FDA approval of Saphnelo (anifrolumab-fnia), for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy.
